Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Three Noteworthy Analyst Calls on Wednesday: Research In Motion Ltd (BBRY), Kohl’s Corporation (KSS)

Page 1 of 2

Sometimes an analyst issues a revised outlook or changes his/her rating, but does not inform investors of the reasons behind the call. These typically move stocks on the call alone; the price target and outlook. However, some analysts provide detailed reasons behind the call; these are the outlooks that should be noted and used as part of your fundamental research. Therefore, I am taking a look at such outlooks and determining the best way to utilize the information.

Kohl's Corporation (NYSE:KSS)

Company Ticker Firm Call
Kohl’s Corporation (NYSE:KSS)
BMO Note
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Piper Jaffray Overweight
Research In Motion Ltd (NASDAQ:BBRY) Pac Crest Note

Acquisition Rumors May Unmask this Retailer’s True Value

Kohl’s initially traded higher by 2.5% on Wednesday, but then closed near flat after BMO issued a note to clients identifying the retailer as a potential buyout target. The firm cited strong cash flow and an attractive valuation as the leading contributors to the firm’s belief.

At first this “prediction” sounded ludicrous to me, as I could not comprehend a retailer or private equity firm having enough capital, or wanting to acquire Kohl’s. However, upon closer consideration, it may make sense.

A 30% premium would be slightly more than $18.5 billion, or 13 times earnings and less than one times sales to acquire Kohl’s. The company’s insiders control just over 2% of the company, meaning a messy takeover with outraged executives would be unlikely. Lastly, the company owns almost 40% of its stores, which is unusual for such stores, and allows a potential acquirer the ability to easily raise capital or refinance debt.

While I do not believe in chasing acquisition rumors — just look at what happened to Life Technologies Corp. (NASDAQ:LIFE) and Office Depot Inc (NYSE:ODP) today — I do believe that all of the potential reasons for an acquirer to buy also relate to the retail investor. This is a cheap stock with a lot of options. I would look hard at Kohl’s.

Analyst Provides a Major Vote of Confidence for this Small Biotech

It has been a volatile year for Threshold Pharmaceuticals, and on Wednesday the stock rallied 11% following a major upgrade and a price target of more than 100% its current price. Over the last 14 months, all eyes have been on the company’s lead product, a late phase product called TH-302, which is used to treat cancers.

Last year a partnership with Merck KGaA(ADR) (PINK:MKGAY) and a 63% upside in progression-free survival helped Threshold become one of the best performing stocks in the market. However, Piper Jaffray took a deeper look at the product, and the company, and is now saying  that TH-302 is superior to rivals when used for soft-tissue sarcoma. The analyst believes the company’s hypoxia-activation platform will be able to be used to treat a wide array of cancers, not just one or two, and sees massive potential down the road.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!